跳至主要内容
临床试验/NCT02118376
NCT02118376Unknown不适用

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
20
试验地点
1
主要终点
Dual energy X-ray absorptiometry

研究概览

简要总结

GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

详细描述

As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1) receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon secretion,and also has the central and peripheral effects,it can inhibit appetite,reduce weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Clinical diagnosis of overweight and type 2 diabetes mellitus

排除标准

  • Poor body condition (severe liver and kidney dysfunction)
  • Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete
  • serious endocrine disease
  • genetic disease

研究组 & 干预措施

exenatide

Experimental

exenatide, 5ug, bid, 3months

干预措施: Exenatide (Drug)

结局指标

主要结局

Dual energy X-ray absorptiometry

时间窗: 3 month

fat distribution

次要结局

  • lab testing(3 month)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhang Manna

Professor

Shanghai 10th People's Hospital

研究点 (1)

Loading locations...

相似试验